Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
|Articles|October 1, 2012
Is it appropriate, or beneficial, to dispense skincare products in dermatology offices?
On Call asked dermatologists around the country whether they dispense prescription or over-the-counter products in their office, why they chose the course they did, what benefits they feel product sales have, and how they choose the products they sell. While the number of dermatologists who offer items for sale is growing, not all offices have gone the retail route.
Advertisement
Advertisement
Related to this article
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Galderma has agreed to acquire ZO Skin Health for $1.5 billion, adding the physician-dispensed skincare brand to a portfolio that already includes Cetaphil and Alastin.
New dermatology research explores hidden steroids in OTC products, infant eczema, melanoma prevention, cutaneous lymphoma, and pediatric AD.
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
An analysis of 633 skincare brands found gaps in evidence, safety information, and claim support, raising questions about what patients can verify online.
Can “Botox in a bottle” really rival injectable neuromodulators? We examine the evidence behind topical peptide serums and Argireline.
Advertisement
Advertisement
Trending on Dermatology Times
1
First-in-Class Oral PKM2 Modulator Shows Early Efficacy in Atopic Dermatitis
2
Alopecia Areata Is a Medical Disease: Treatment Options and Defining Severity
3
AI-Era Skincare Report Finds Widespread Gaps in Verifiable Product Claims
4
Galderma to Acquire ZO Skin Health for $1.5 Billion
5